BRAF and colorectal carcinoma: It has been suggested that RNF43-mutated can be used as a predictive biomarker of anti-BRAF/EGFR combination therapy response in microsatellite-stabilized (MSS) BRAF V600E metastatic colorectal cancer patients, and RNF43-mutated is a better predictive biomarker of progression-free survival (PFS) and OS in BRAF-mutated CRC patients (9, 11).